Pharma — AI Drug Discovery Sovereignty
Pharmaceutical sovereignty, computationally manufactured.
Pharma compresses the discovery-to-validation arc with sovereign-trained generative biology. Virtual molecule design, target deconvolution, and antimicrobial-resistance surveillance ship together — under data residency that aligns with the EU Critical Medicines Act, GCC localization mandates, and Indian sovereign-AI doctrine.
Why this vertical needs a sovereign solution.
The EU Critical Medicines Act, GCC strategic procurement mandates, and India's bio-self-reliance doctrine all converge on a single requirement: pharmaceutical capacity that does not rely on foreign cloud stacks, models, or molecule libraries. The world's largest discovery platforms cannot meet that bar by design.
How Pharma works.
Sovereign-trained generative chemistry
Diffusion and transformer-based molecule design tuned against indigenous chemical libraries and target sets. Outputs are exportable without phoning home.
Virtual trial simulation
Patient-cohort simulation, mechanism modeling, and adverse-event forecasting before any wet-lab spend.
AMR surveillance grid
Antimicrobial-resistance pattern detection across hospital, agricultural, and environmental signals — the first sovereign-grade AMR intelligence layer.
Sovereign-grade research, end to end.
- Generative small-molecule and biologic design
- Target identification and validation in-silico
- ADMET, toxicity, and PK/PD prediction
- Virtual cohort and trial simulation
- AMR genomic surveillance and outbreak intelligence
- Regulatory grammar fluency — EMA, CDSCO, GCC HA
- Air-gap-deployable compute stack
Sovereign customers, on the record.
Sovereign pharma champions
National pharma anchors mandated to localize discovery and reduce dependence on foreign IP pipelines.
Health ministries and HERA-aligned buyers
Procurement bodies executing pharmaceutical-sovereignty policy with concrete vendor mandates.
Generics-to-novel ladder companies
Generics players climbing into NCE and biologics R&D, in need of a sovereign discovery cockpit.
Three patterns we deploy at sovereign scale.
National critical-medicines pipeline
Identify and design replacements for foreign-controlled critical drugs — generics, biologics, and orphan compounds — entirely within sovereign infrastructure.
AMR national defense layer
Detect resistance patterns across hospital and agricultural surveillance, model spread, and prioritize stewardship interventions.
In-silico Phase 0
Compress 18 months of pre-clinical exploration into 90 days of virtual experimentation before committing to wet-lab spend.
One platform. Pharma is a lens.
Pharma sits on MEDHxLLamaXOpenHathi for regulatory and target reasoning, MEDHxBERT for literature mining, MEDHxRESTNET50 for assay-image classification, and MEDHxAKAZE for histology endpoints. The whole stack is one platform; Pharma is a sovereign-grade lens on it.